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a b s t r a c t
Background: Fisherfolks (FF) and female sex workers (FSW) in Uganda could be suitable key populations
for HIV vaccine efficacy trials because of the high HIV incidence and good retention in observational
cohorts. However, the observed HIV incidence may differ in participants who enroll into a trial. We used
simulated vaccine efficacy trials (SiVET) nested within observational cohorts in these populations to eval-
uate this difference.
Methods: SiVETs were nested in two observational cohorts (Jul 2012–Apr 2014 in FF and Aug 2014–Apr
2017 in FSW). From Jan 2012 all observational cohort participants (aged 18–49 years) presenting for
quarterly visits were screened for enrolment into SiVETs, until 572 were enrolled. Those not enrolled
(screened-out or not screened) in SiVET continued participation in the observational cohorts. In addition
to procedures in the observational cohorts (HIV testing & risk assessment), SiVET participants were given a
licensed Hepatitis B vaccinemimicking a schedule of a possible HIV vaccine, and followed-up for 12months.
Findings: In total, 3989 participantswere enrolled into observational cohorts (1575 FF prior to Jul 2012 and
2414 FSW prior to Aug 2014). Of these 3622 (90.8%) returned at least once, 672 (44.1%) were screened and
572 enrolled in the SiVETs. HIV incidence pre SIVETs was 4.5/100 person years-at-risk (pyar), 95%CI (3.8–
5.5). HIV incidence in SiVET was 3.5/100 pyar, (2.2–5.6) and higher in those not enrolled in the SiVET,
5.9/100 pyar, (4.3–8.1). This difference was greatest among FF. In the 12 months post-SIVET period (FF,
May 2014–Apr 2015 and FSW, May 2017–Apr 2018), the HIV incidence was 3.7/100 pyar, (2.5–5.8).
Interpretation: HIV incidence was lower in SiVET participants compared to non-SiVET. This difference was
different for the two populations. Researchers designing HIV efficacy trials using observational cohort data
need to consider the potential for lower than expected HIV incidence following screening and enrolment.
 2019 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
The burden of HIV continues to be a global challenge but there
are several opportunities for HIV prevention, including antiretrovi-
ral therapy (ART) for those living with HIV, and Pre Exposure Pro-
phylaxis (PrEP) for HIV uninfected partners. The high HIV burden
has been attributed to less than optimal adherence to the available
HIV prevention interventions [1,2], and an HIV vaccine would be a
very useful addition. Rigorous assessment of such a vaccine
through randomized controlled efficacy trials would be needed,
but there are methodological issues facing such trials [3]. Popula-
tions with high HIV incidence, good retention in follow up and ade-
quate access and use of HIV services are needed to conduct
successful HIV vaccine efficacy trials [4]. In countries, where the
general population HIV incidence is relatively low [5,6], these trials
will have to be conducted among sub-populations who are at high
risk of HIV acquisition. Such sub-populations could include men
and women with multiple partners or who live in high HIV preva-
lence areas, such as the fishing communities on Lake Victoria (Fish-
erfolks, FF) shoreline and female sex workers (FSW) in Kampala.
In Uganda, HIV incidence data are available from observational
cohort in FSW [7,8] and FF [9–13]. Observational cohort data may
not always predict efficacy trial outcomes because the efficacy trial
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environment is highly controlled with respect to adherence to trial
product, clinic visits and HIV risk reduction measures. In addition,
there is evidence that participants who join clinical trials differ
from those in the source population [14]. Participants who join
the clinical trial may have a different HIV incidence from that esti-
mated from the wider observational cohort. Such differences may
affect the sample size and power estimates that are used to plan
efficacy trials.
One systematic review [15] identified six HIV prevention stud-
ies that were unsuccessful and/or terminated because of reduced
statistical power, due to observing lower HIV incidence during par-
ticipant follow up than that predicted based on observational data.
The lower than anticipated HIV incidence happened in 64% of the
trials evaluated [15]. In three microbicides trials in Nigeria [16]
and Ghana [17,18] in 2007/8, an HIV incidence of 5 per 100 person
years at risk (PYAR) was predicted in the placebo arms of the trial
communities. During the trial, the observed HIV incidence in the
respective trial placebo arms were 1.5 per 100 PYAR [16], 1.1 per
100 PYAR [17] and 2.5 per 100 PYAR [18], resulting in the trials
being stopped prematurely. On the contrary, a trial in South Africa
in 2016 [19] observed an HIV incidence of 3.9 per 100 PYAR prior to
the trial, but during participant follow up in the placebo arm of the
trial, the HIV incidence was more than 5 per 100 PYAR. This
resulted in the investigator re-calculation of the sample size to a
lower figure than that planned and they observed an HIV incidence
of 4.5 per 100 PYAR in the placebo arm at the end of trial follow up.
These discrepancies show that observational data need to be used
with caution while planning HIV vaccine efficacy trials, especially
in populations without baseline data from previous efficacy trials
such as the FF in Uganda.
The simulated vaccine efficacy trial (SiVET) concept has been
suggested to assess feasibility, acceptability and retention for a
clinical trial of a new product, through a ‘‘simulated” trial using a
commercially available vaccine [20,21]. This concept can also
inform designs and sample size estimation for the future trials
[22–24]. We use data from two SiVETs nested within observational
cohorts of FSW and FF sub-populations in Uganda, to estimate HIV
incidence, in order to help plan a future HIV vaccine efficacy trial.
2. Methods
2.1. Study design
We use data from two longitudinal observational cohorts in
Uganda (observational cohort one (OBSC1) in FF, Feb 2009–Apr
2015 and observational cohort two (OBSC2) in FSW, Apr 2008–
Apr 2018). The primary objective of establishing the observational
cohorts was to determine HIV incidence and retention in follow up
of these key populations in addition to creating enrolment pool for
future HIV efficacy trials. From those observational cohorts, two
SiVETs (SIVET1 (Jul 2012–Apr 2014) and SiVET2 (Aug 2014–Apr
2017)) were nested within OBSC1 and OBSC2 respectively. The
eligibility criteria for the observation cohorts and the SiVETs are
shown in Table 1.
2.2. Description of observational cohorts and SiVETs
2.2.1. Obsc1
Eligible participants (Table 1) were enrolled into OBSC1 at MRC/
UVRI and LSHTM clinics supported by International AIDS Vaccine
Initiative located in Masaka town (about 50 km) from the fishing
communities (about 100 km west of Kampala) with quarterly fol-
low up clinic visits for HIV testing and six-monthly visits for HIV
behavioral risk assessment. At enrolment, data were also recorded
on participants’ socio demographic and clinical characteristics
using interviewer administered questionnaires. The OBSC1 details
are previously described [9,12,13]. From Jul 2012 to Apr 2014, FF
attending the OBSC1 clinic were assessed for eligibility (Table 1)
for enrolment into SiVET1.
2.2.2. Obsc2
Similarly, eligible participants (Table 1) were enrolled into
OBSC2 at MRC/UVRI and LSHTM clinic in Kampala with similar
assessments and follow up schedules as OBSC1 above. The OBSC2
details have been previously described [7]. Similarly, from Aug
2014 to May 2016, FSW attending the quarterly clinic visits in
OBSC2 were assessed for eligibility for enrolment into SiVET2
(Table 1).
2.2.3. SiVET1
Eligible participants (Table 1) were enrolled into SIVET1 (nested
in OBSC1 in the FF population) and had their follow up visits in
SiVET1 synchronized with their source OBSC1 participants clinic
visits for HIV and behavioral risk assessment. In addition to their
OBSC1 procedures, they were further administered a commercially
licensed Hepatitis B vaccine (ENGERIX-BTM GlaxoSmithKline Biolog-
icals Rixensart, Belgium) following the standard schedule of 0, 1
Table 1
Observational cohorts and SiVETs eligibility criteria in the three periods.
Time OBSCs pre SiVETs
Period
(i)
Inclusion
 HIV negative and willing to undergo HIV testing
 Age 18–49 years
 Able and willing to provide written informed consent
 Willing to provide adequate locator information
 Available for follow-up
 Sexually active and at high risk for HIV infection as defined by
self-report of any of the following in the previous 3 months:
(a) Unprotected sex with one or new sexual partner
(b) History of sexually transmitted infections
(c) Use of illicit drugs and/or alcohol
(d) Being away from home for 2 nights per week
 Engaged in sex work (only OBSC2) Exclusion
 HIV infection
Period
(ii)
SiVETs
Inclusion
 At least 3 and no more than 18 months of follow up in the
observational cohort
 HIV-1 negative and willing to undergo HIV testing
 Aged 18 years and 49 years
 Able and willing to provide written informed consent
 Able and willing to provide adequate locator information
 Willing and able to return for follow-up clinic visits
 Intending to reside in study area for at least one year
 Willing to undergo pregnancy testing
 Not breastfeeding and no intent for pregnancy in the next year
 Willing to use effective contraception during the study and at
least 3 months after the last vaccination
Exclusion
 History of severe allergic reaction to any substance
 An acute or chronic illness
 Contraindication for Hepatitis B vaccine
 Participation in another clinical trial
 Hepatitis B positive (only SiVET2)
Non-SiVETs concurrent period
Inclusion
 At least 3 months and no more than 18 months of follow up in
the observational cohorts
 Still in active follow up in the observational cohort
 HIV negative
Exclusion
 HIV positive
Period
(iii)
Post- SiVETs
Inclusion
 HIV NegativeExclusion
 HIV positive
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and 6 months, and under conditions that mimicked a possible HIV
vaccine efficacy trial with extra follow ups at 9 and 12 months
under the SiVET1 protocol. Upon completion of SiVET1 follow up,
participants were followed-up under OBSC1 procedures only, for
another12 months (post-SiVET1).
2.2.4. SiVET2
Similar procedures as in SiVET1 above were followed to establish
SiVET2, though this was nested in OBSC2 in the FSW population.
Observational cohort participants that were eligible for screen-
ing for enrollment into SiVETs but not screened because of comple-
tion of SiVETs accrual, and those screened but not enrolled into
SiVETs (i.e., screened out by SiVET enrollment criteria), remained
in follow-up in their respective observational cohorts during the
SiVET concurrent period (Fig. 1).
When SiVET participants completed 12 months of follow up in
the SiVET protocol, they automatically reverted to the post-SiVET
cohorts, joining the non-SiVET participants for further follow-up
and HIV incidence assessment.
We stratified our data into three periods for each source popu-
lation (FF or FSW), as shown in Fig. 1:
(1) Pre-SiVETs period (i), including only observational cohort
data prior to the initiation of the SiVET in that source
population.
(2) SiVET period (ii), including both non-SiVET data and data
from the SiVET participants (mutually exclusive) beginning
on the date the SiVET began enrolling, and ending on the
date of the last SiVET participant clinic visit.
(3) Post-SiVET period (iii), including all observational cohort
data recorded after the final SiVET participant study visit
(including new recruits) in that source population.
As indicated in Fig. 1, the 3622 participants analyzed in obser-
vational cohorts were the basis for period (i) incidence estimates.
The 1525 participants eligible for screening for enrollment into
SiVETs were the basis for period (ii) incidence estimates for both
the SiVET and non-SiVET cohorts, and the 886 participants ana-
lyzed for HIV incidence post-SiVET were the basis for period (iii)
incidence estimates.
2.3. Key evaluations in this analysis
 Participant baseline characteristics, compared between
SiVETs data and non-SiVET data in the concurrent period (ii).
 HIV incidence in SiVET compared to that in the observational
pre-SiVET cohort, the concurrent non-SiVET cohort, and
post-SiVET cohort.
2.4. Laboratory HIV testing
All HIV testing was carried out at the MRC/UVRI and LSHTM
clinical diagnostic laboratories. A single HIV antibody rapid test
was performed using Alere DetermineTM HIV-1/2 (Alere Medical
Co Ltd, Matsuhidai, Matsudo-shi, Chiba, Japan). All rapid HIV posi-
tive results were confirmed by two parallel enzyme linked
immunosorbent assay (ELISA) tests (Murex Biotech Limited, Dart-
ford, United Kingdom, and Vironostika, BioMérieux boxtel, The
Netherlands). Either Statpak (Chembio Diagnostic Systems Inc.,
USA) or Western Blot (Cambridge Biotech, USA) confirmed any dis-
cordant results.
2.5. Data management and statistical analysis
All observational cohort data were entered and managed in MS
Access 2003 (Microsoft Corporation, Redmond, WA), and SiVET
data in OpenClinica 3.5 (Waltham, MA). Data were analyzed in
Stata 14.0 (Stata Corp, College Station, TX, USA). Baseline charac-
teristics of the participants in the non-SiVET cohort (period ii, con-
current non-SiVET data) and those that joined SiVETs (period ii,
SiVET) were summarized using percentages, stratified by the study
population (FF or FSW) and compared using chi square tests. We
estimated HIV incidence as the number of HIV positive cases in a
given period divided by the total person years at risk (PYAR) in
the same period expressed as per 100 PYAR. PYAR were calculated
as the sum of the time from the period specific analysis entry date
to the date of the last HIV seronegative result, or to the estimated
date of HIV infection. The date of HIV infection was defined as a
random (multiple imputation) date between last HIV-negative
and the first HIV-positive result dates. The analysis entry dates
were defined in the three respective periods as follows: period
(i), date of enrolment into a given observational cohort; period
(ii) concurrent non-SiVET cohort, three months visit date in the
observational cohort (from the start of a given SiVET); period (ii)
SiVETs data; date of enrolment into a given SiVET and period (iii)
post-SiVET period; date of completion of a given SiVET or date of
enrolment for those enrolled post-SiVET.
To put the results in the context of an actual HIV vaccine effi-
cacy trial, we estimated required sample sizes using HIV incidence
in period i, and ii (SiVETs data). First, overall and stratified by the
study population. We compared the sample size estimated using
HIV incidence in period (i) to that in period ii (SiVETs data) to esti-
mate the magnitude of decrease (loss in statistical power) if obser-
vational data HIV incidence in period (i) were used to estimate trial
sample size as opposed to SiVETs i.e. period (ii) (SiVETs data).
While estimating the required sample sizes, we based on the fol-
lowing design; an HIV vaccine efficacy trial uses a superiority study
design, an investigational product likely to reduce background HIV
incidence by 70%, statistical power of 80%, two-sided alpha of 5%
and same loss to follow up in the observational cohorts as in the
SiVETs.
2.6. Ethical considerations
The Uganda Virus Research Institute (UVRI) Research and Ethics
Committee (GC127, GC/127/14/04/454, GC/127/12/04/22 and
GC127/12/06/01) and the Uganda National Council for Science
and Technology (MV834, HS364 and HS1584) approved the con-
duct of observational cohorts and SiVET protocols. The London
School of Hygiene and Tropical Medicine Observational/Interven-
tions Research Ethics Committee (LSHTM14588) approved the con-
cept leading to this analysis. Written informed consent/assent was
obtained for each participant before enrolment. All participants
diagnosed to be HIV positive were immediately referred to the
local HIV related service providers in the community for treatment
and care.
3. Results
3.1. Screening, enrolment and follow up in observational cohorts pre
SiVETs, period (i)
In total, 5902 participants were screened and 3989 (67.6%)
enrolled into observational cohorts pre SiVETs, period (i). The med-
ian age was 26 years (interquartile range, IQR: 22–32). The primary
reasons for not enrolling were HIV positive (n = 739), low risk for
HIV infection (n = 681) and, for OBSC2, not in sex work (n = 430)
Fig. 1. Of those enrolled, 3622 (90.8%) completed at least one
follow up visit in the observational cohorts and were analysed to
determine HIV incidence pre SiVETs, period (i). The primary
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reasons for not returning for any follow up were participant moved
out of study area (n = 186) and being uncontactable (n = 154).
3.2. Screening, enrolment & follow-up in the concurrent non-SiVET
cohort & SiVET, period (ii)
Of the 3622 participants that returned for at least one follow up
visit in the observational cohorts pre SiVETs, 1525 (42.1%) were
eligible for screening into SiVETs when the SiVET protocols were
introduced and 2097 (57.9%) were not eligible. The primary rea-
sons for ineligibility were having been in the observational cohorts
for 18 months (n = 1871), exiting observational cohort before
SiVETs roll out (n = 121) and being HIV positive (n = 105) Fig. 1.
Of the 1525 (median age 26 years IQR: 22–31) eligible for screen-
ing, 672 (44.1%) were screened (under 50% were screened because
of sample size accrual) and 572 (85.1%) enrolled into SiVETs. The
primary reasons for not enrolling into SiVETs were previous hep-
atitis B exposure (n = 52), not willing to use contraception (n = 9),
pregnancy (n = 8) and not returning for enrolment (n = 8). In total,
953 (62.5%) of 1525 eligible for screening into SIVETs remained in
follow up in the non-SiVET cohorts in the SiVETs concurrent period
(period (ii) non-SIVET data) Fig. 1. Retention at 12 months was
Fig. 1. Study profile for participants screened and enrolled Pre, during and post SiVET in two key populations in Uganda.
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83.8% in SiVETs vs. 76.4% in non-SiVET cohorts in the concurrent
period (ii), p < 0.01.
In the OBSC1, compared to those that were not eligible for
screening into SiVET1, eligible participants were younger (mean
age 26.5 vs 28.5: p = 0.038), mostly males 60.5% vs 54.8%,
p = 0.029 and were less likely to have lived for more than one year
at the current location 59.8% vs 75.2%, p < 0.001 but were other-
wise similar in terms of other characteristics. Similarly, in the
OBSC2, compared to those that were not eligible for screening into
SiVET2, eligible participants were more likely to have lived at the
current location for more than one year 91.5% vs 68.5%, p < 0.001
but were otherwise similar in terms of other characteristics.
3.3. Post SiVETs, period (iii)
In total 1168, participants (1083 from period ii and 85 new
recruits into observational cohorts post-SiVETs) were followed up
quarterly for 12 months in the observational cohorts post-SiVETs,
period (iii). Retention at 12 months was 84.6%.
3.4. Baseline characteristics, SiVETs vs non-SiVET cohorts in the
concurrent period (ii)
Table 2, presents the baseline characteristics of the participants
who were recruited into SiVET1 (FF) and SiVET2 (FSW) compared to
those in the source population who were not recruited into the
SiVETs (non-SiVET1 and non-SiVET2) in the same period (ii). In
the FF population, compared to SIVET1, non-SiVET1 cohort had
greater numbers of females 51.6% vs 27.3%, those aged 18–24 years
44.9% vs 31.2%, those without formal education 12.4% vs 6.7%,
those working in Hotel/Bar/Hair salon 23.0% vs 8.2%, and those that
had lived at the current location for one year or less 33.9% vs 17.0%.
Similarly, in the FSW population, compared to SiVET2, non-SiVET2
cohort had greater numbers of participants aged 18–24 years
45.4% vs 29.3%, those without formal education 40.6% vs 5.5%,
those engaged in sex work 67.5% vs 56.9% [noting that there are
FSW who don’t consider sex work as their main occupation] and
those that had lived at the current location for one year or less
33.1% vs 17.6%.
3.5. HIV incidence in periods i, ii and iii
The HIV incidence in the SiVETs (period ii) was lower than that
in the observational cohorts pre-SiVETs (period i), and the concur-
rent incidence in the non-SiVET cohorts during period ii (Table 3).
The HIV incidence in the post-SiVET observational cohorts (period
iii) was lower than that in the pre-SiVET observational cohorts i.e.
period (i) and similar to the HIV incidence in the SiVET cohort in
period (ii), (Table 3). In all periods, HIV incidence was higher in
the FF population than FSW population. HIV incidence was greater
Table 2
Baseline characteristics of the participants in the non-SiVET and SiVET cohorts, period (ii) in Masaka and Kampala.
Period (ii), FF (N = 565) Period (ii), FSW (N = 960
Variables Overall n (%) Non-SiVET1 n (%) SiVET1 n (%) p-value Overall n (%) Non-SiVET2 n (%) SiVET2 n (%) p-value
Overall 565 (100) 283 (100) 282 (100) – 960 (100) 670 (100) 290 (100) –
Sex –
Male 342 (60.5) 137 (48.4) 205 (72.7) <0.001
Female 223 (39.5) 146 (51.6) 77 (27.3) 960 (100) 670 (100) 290 (100)
Age group (years)
18–24 215 (38.1) 127 (44.9) 88 (31.2) 0.001 389 (40.5) 304 (45.4) 85 (29.3) <0.001
25–34 242 (42.8) 115 (40.6) 127 (45.0) 432 (45.0) 289 (43.1) 143 (49.3)
35+ 108 (19.1) 41 (14.5) 67 (23.8) 139 (14.5) 77 (11.5) 62 (21.4)
Tribe
Baganda 242 (42.8) 114 (40.2) 128 (45.4) 0.018 448 (46.7) 295 (44.0) 153 (52.8) 0.035
Banyankole 81 (14.3) 50 (17.7) 31 (11.0) 141 (14.7) 109 (16.3) 32 (11.0)
Banyarwanda 123 (21.8) 69 (24.4) 54 (19.2) 60 (6.2) 40 (6.0) 20 (6.9)
Other 119 (21.1) 50 (17.7) 69 (24.4) 311 (32.4) 226 (33.7) 85 (29.3)
Education
None 54 (9.5) 35 (12.4) 19 (6.7) 0.046 288 (30.0) 272 (40.6) 16 (5.5) <0.001
Primary 401 (71.0) 190 (67.1) 211 (74.8) 431 (44.9) 282 (42.1) 149 (51.4)
Secondary+ 110 (19.5) 58 (20.5) 52 (18.5) 241 (25.1) 116 (17.3) 125 (43.1)
Marital status
Single never married 170 (30.1) 86 (30.4) 84 (29.8) 0.173 308 (32.1) 240 (35.8) 68 (23.5) 0.001
Married 268 (47.4) 125 (44.2) 143 (50.7) 60 (6.2) 42 (6.3) 18 (6.2)
Single ever married 127 (22.5) 72 (25.4) 55 (19.5) 592 (61.7) 388 (57.9) 204 (70.3)
Religion
Christian 433 (76.6) 216 (76.3) 217 (77.0) 0.861 726 (75.6) 507 (75.7) 219 (75.5) 0.959
Muslim 132 (23.4) 67 (23.7) 65 (23.0) 234 (24.4) 163 (24.3) 71 (24.5)
Occupation
Fishing/fish related 293 (51.8) 124 (43.8) 169 (59.9) <0.001 – – – 0.019
Small scale business 132 (23.4) 59 (20.8) 73 (25.9) 28 (2.9) 17 (2.5) 11 (3.8)
Hotel/Bar/Hair saloon 88 (15.6) 65 (23.0) 23 (8.2) 307 (32.0) 196 (29.3) 111 (38.3)
Sex work – – – 617 (64.3) 452 (67.5) 165 (56.9)
Other 52 (9.2) 35 (12.4) 17 (6.0) 8 (0.8) 5 (0.7) 3 (1.0)
Duration lived at the current location (years)
0–1 144 (25.5) 96 (33.9) 48 (17.0) <0.001 273 (28.4) 222 (33.1) 51 (17.6) <0.001
>1 421 (74.5) 187 (66.1) 234 (83.0) 687 (71.6) 448 (66.9) 239 (82.4)
Illicit drug use 187 (19.5) 132 (19.7) 55 (19.0) 0.791
No 499 (88.3) 254 (89.7) 245 (86.9) 0.288 773 (80.5) 538 (80.3) 235 (81.0)
Yes 66 (11.7) 29 (10.2) 37 (13.1)
SiVET-Simulated Vaccine Efficacy Trial.
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in the non-SiVET than in the corresponding SiVET in the concurrent
period i.e. period (ii), and the difference was highest in the FF pop-
ulation 8.3 per 100 PYAR vs 3.8 per 100 PYAR, p = 0.017 compared
to FSW population 4.1 per 100 PYAR vs 3.2 per 100 PYAR, p = 0.300.
However, the difference in the FSWwas not statistically significant.
Supplementary Table 4 shows HIV incidence by the different
characteristics of the participants in the three periods. In all the
periods, HIV incidence tended to be higher among participants that
had spent one year or less in the current location and lower among
Baganda (indigenous occupants of the geographical location of the
two study areas), but it varied in the other participant characteris-
tics in the different periods.
3.6. Contextualizing HIV incidence observed to actual HIV vaccine
efficacy trial
Putting these results in the context of a future HIV vaccine effi-
cacy trial, a sample size can be calculated using the overall HIV
incidence in the SiVETs of 3.5/100 PYAR. With that HIV incidence
in the control (placebo) arm of the trial, the actual sample size
would be 1626 participants (813 in each arm) to show an incidence
risk ratio (RR) of 0.30 with a significance of 5% and power of 80%.
However, in absence of the SiVETs, the HIV incidence in the control
arm would be estimated from the HIV incidence of 4.5/100 PYO in
the pre-SiVETs (period i). In that case the estimated sample size
would be 1266 participants (633 in each arm) to show the RR of
0.30, with a significance of 5% and a power of 80%. This would
under estimate the true trial sample size by 360 participants, an
under estimate of 22% of the expected number of study partici-
pants and only achieve 67.8% power. The direction of underesti-
mate in the sample size was similar in each of the sub-
populations (FF and FSW), and calculations of sample size based
on the pre-SiVET HIV incidence would give reduced power for
the HIV incidence observed under the SiVET selection with the
highest reduction in the FF population.
4. Discussion
In this analysis, we investigated how HIV incidence in two HIV
Simulated Vaccine Efficacy Trials (SiVETs) differs from the observa-
tional cohorts within which they were nested. We compared HIV
incidence in SiVETs to that in the observational cohorts, in the
pre-SiVET period, the concurrent non-SiVET cohort, and post-
SiVETs periods. The combined HIV incidence in the SiVETs (3.5
per 100 PYAR) was lower than in the observational pre-SiVET com-
bined cohort (4.5 per 100 PYAR) and the concurrent non-SiVET
cohort (5.9 per 100 PYAR). The HIV incidence in the post-SiVETs
observational cohorts was similar to that in the SiVETs. Stratifying
the results by the study population, we found the same pattern in
each, with a greater difference in the population of Fisherfolk.
Our findings suggest the likely effect of selection into trials
and/or trials environment on background HIV risk. We conjec-
ture two possible causes of these differences: (a) people who
volunteer to take part in trials have lower risk of HIV infection,
and (b) the trial environment changes people’s behavior, which
results in lower risk of HIV infection. These two causes are not
mutually exclusive. Although the observational cohorts were
the recruitment source for the SiVETs, participants who joined
SiVETs differed in important ways from those who did not. The
proportions of each of male sex, those aged over 25 years, with
formal education, and having lived in the community for over
one year were higher in the SiVET cohort than in the non-
SiVET cohort. These participant characteristics have been
previously associated with lower risk of HIV acquisition in these
populations [8,11,13,25] and other HIV at-risk populations
[26–29]. The selection difference between trials and source
population have been previously highlighted [14,17].
Secondly, the reduction in HIV incidence could be attributable
to the difference between the trial and observational cohort envi-
ronment. This has been previously noted in microbicides trials in
West Africa [16–18]. In these trials, investigators observed a reduc-
tion in HIV incidence in the placebo arms during participants fol-
low up of between 50% and 78% from that predicted at baseline.
These trials were prematurely terminated. The investigators
hypothesized that diminished HIV incidence within a trial may fol-
low from vigorous responses to trial HIV risk-reduction measures
and a possible inclination to safer HIV risk behavior. Furthermore,
HIV incidence in earlier trials in a similar population was used to
plan the current trials instead of specifically measuring incidence
in each population before starting a trial. In the case of SiVETs in
both FF and FSW, we provided HIV risk reduction measures (coun-
selling on multiple concurrent sexual partnership, condom use and
being faithful to one partner), provided free condoms as well as
active diagnosis and treatment for STIs and other genital infections.
These were as well provided to the non-SiVET cohorts except con-
doms were provided on request and no active diagnosis and treat-
ment for STIs and other genital infections was done. These HIV risk
reduction interventions in an efficacy trial could lower the risk of
HIV infection during participant follow up even in the absence of
a preventive HIV vaccine or other investigational product.
Our findings build on the results of an earlier pilot analysis [30]
of the data from the FF population. The pilot analysis was smaller,
in one study population, with shorter follow up in the observa-
tional cohort and showed a bigger difference between the HIV inci-
dence in the SiVET cohort (3.8 per 100 PYAR) and the non-SiVET
cohort (11.4 per 100 PYAR).
In our estimation of the required sample size, the results overall
show that using HIV incidence from observational data to plan a
possible HIV vaccine efficacy trial would underestimate the trial
sample size by about one-quarter. This sample size underestima-
tion, achieves a statistical power of 68%. The underestimation of
the study size was highest in the Fisherfolk population.
Our study strengths included an adequate follow up period in
the pre, concurrent and post SiVETs periods, sufficient sample size,
two key populations in different geographical location, same study
teams conducting study procedures in the respective populations
and comparing SiVETs participants to non-SiVET participants in
Table 3
Overall HIV incidence pre, during and post-SiVET and stratified by the study population.
Period (i) Period (ii) Period (iii)
Target population HIV+/PYAR Incidence (95%CI) Non-SiVET data SiVET data
HIV+/PYAR Incidence (95%CI) HIV+/PYAR Incidence (95%CI) HIV+/PYAR Incidence (95%CI)
Fisherfolk 69/1404.9 4.9 (3.9–6.2) 24/289.5 8.3 (5.6–12.4) 10/263.5 3.8 (2.0–7.1) 12/291.2 4.1 (2.3–7.3)
FSW 36/904.8 4.0 (2.9–5.5) 15/368.6 4.1 (2.5–6.7) 7/221.4 3.2 (1.5–6.6) 9/266.1 3.4 (1.8–6.5)
Overall 105/2309.7 4.5 (3.8–5.5) 39/658.1 5.9 (4.3–8.1) 17/484.9 3.5 (2.2–5.6) 21/557.3 3.7 (2.5–5.8)
PYAR: person years at risk, SiVET: Simulated Vaccine Efficacy Trial, CI: confidence interval, FSW: Female sex work, HIV+: HIV positive cases.
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the same population and period. The results provide strong evi-
dence to researchers planning HIV vaccine efficacy trials in these
populations that, in communities with a high HIV burden, HIV inci-
dence observed in existing observational cohorts might differ from
that they will see in trials even in the absence of a preventive vac-
cine or other interventions.
Our study limitations included; the procedures in SiVETs and
observational cohorts were not blinded (to either participants
and/or researchers) and were performed by the same study teams.
However, at the time of SiVET roll out, the primary objective was
not to compare attributes in the two studies and therefore the lack
of blinding may or may not have affected measurement of out-
comes considered in this analysis. Although recruitment into
SiVETs had a run-in period of at least three months, an actual vac-
cine efficacy trial may not wait this long. Selection bias could have
played a role in recruitment of participants into SiVETs. This could
be inform of self-selection or the study teams recruited into SiVETs
participants that came on time for their observational cohort visits
(SiVETs screening visits). Such participants could have been easier
to follow up and likely to come from the low-risk strata (older, men
(FF population) and residents for a longer time).
In conclusion, in two key populations, FF and FSW, we have
seen that people who volunteer for a vaccine trial are different
from the source population in crucial ways. These differences,
together with a trial environment, could result in lower HIV inci-
dence in both arms of a trial, even in the absence of an effective
HIV vaccine or other biomedical intervention. SiVET HIV incidence
could be a useful aid for sample size calculations for future HIV
vaccine trials. In populations where such data is not available,
we recommend use of the observed incidence in observational
cohorts but adjusting the sample size by approximately one quar-
ter to accommodate for the likely lower incidence in the trial. This
strategy could provide a better estimate. Interestingly, even with
these differences, the HIV incidence in these key populations
remains high, in an era of wide spread use of antiretroviral treat-
ment, and while reduced in SiVETs, it is still suitable for actual
HIV vaccine efficacy and other intervention trials.
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